Cardiovasc Endocrinol Metab (2018) 7:803
Sedenho-Prado LG, Yugar LBT, Whitaker AR, Martins MP, Jesus DC, Ferreira I, et al
Originally developed and FDA-approved for managing type 2 diabetes, Ozempic belongs to a group of medications known as GLP-1 receptor agonists
Start todayMore Info Potential Weight Loss* Administration methods** Oral Drops Injections Lozenges Dose frequency*** Weekly or Daily Potential side effects Possible side effects may include nausea, vomiting, constipation, diarrhea, indigestion or stomach discomfort, reduced appetite, headache, fatigue, or injection site reactionsespecially when starting or increasing the dose
Not because they're negligent
Thus, among women randomized to the highest retatrutide dose, percentage mean weight loss at 48 weeks was 28.5% versus 21.9% among men